Onyx Pharms Amgen Drug Patent Portfolio
Onyx Pharms Amgen owns 1 orange book drug protected by 12 US patents Given below is the list of Onyx Pharms Amgen's drug patents along with their expiration dates.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same | 27 Feb, 2033 | Active |
US9511109 | Combination therapy with peptide epoxyketones | 21 Oct, 2029 | Active |
USRE47954 | Combination therapy with peptide epoxyketones | 21 Oct, 2029 | Active |
US7737112 | Composition for enzyme inhibition | 07 Dec, 2027 | Active |
US7417042 | Compounds for enzyme inhibition | 20 Jul, 2026 | Active |
US7232818 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
US7491704 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
US8129346 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
US8207125 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
US8207126 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
US8207127 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
US8207297 | Compounds for enzyme inhibition | 14 Apr, 2025 | Active |
Latest Legal Activities on Onyx Pharms Amgen's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Onyx Pharms Amgen.
Activity | Date | Patent Number |
---|---|---|
Payment of Maintenance Fee, 8th Year, Large Entity | 30 Apr, 2024 | US9493582 |
Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8207297 (Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8207125 (Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8207127 (Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 21 Nov, 2023 | US8207126 (Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 22 Aug, 2023 | US8129346 (Litigated) |
Correspondence Address Change
Critical
| 04 Dec, 2022 | US9493582 |
Payment of Maintenance Fee, 12th Year, Large Entity | 01 Dec, 2021 | US7737112 (Litigated) |
Payment of Maintenance Fee, 12th Year, Large Entity | 06 Aug, 2020 | US7491704 (Litigated) |
Payment of Maintenance Fee, 4th Year, Large Entity | 30 Apr, 2020 | US9493582 |
Payment of Maintenance Fee, 12th Year, Large Entity | 13 Feb, 2020 | US7417042 (Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 13 Dec, 2019 | US8207125 (Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 13 Dec, 2019 | US8207297 (Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 13 Dec, 2019 | US8207127 (Litigated) |
Payment of Maintenance Fee, 8th Year, Large Entity | 13 Dec, 2019 | US8207126 (Litigated) |
Onyx Pharms Amgen's Family Patents
Onyx Pharms Amgen Drug List
Given below is the complete list of Onyx Pharms Amgen's drugs and the patents protecting them.
1. Kyprolis
Kyprolis is protected by 12 patents, out of which none have expired yet. Check out its patent list below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
US9493582 | Alkylated cyclodextrin compositions and processes for preparing and using the same |
27 Feb, 2033
(8 years from now)
| Active |
US9511109 | Combination therapy with peptide epoxyketones |
21 Oct, 2029
(4 years from now)
| Active |
USRE47954 | Combination therapy with peptide epoxyketones |
21 Oct, 2029
(4 years from now)
| Active |
US7737112 | Composition for enzyme inhibition |
07 Dec, 2027
(2 years from now)
| Active |
US7417042 | Compounds for enzyme inhibition |
20 Jul, 2026
(1 year, 7 months from now)
| Active |
US7232818 | Compounds for enzyme inhibition |
14 Apr, 2025
(3 months from now)
| Active |
US7491704 | Compounds for enzyme inhibition |
14 Apr, 2025
(3 months from now)
| Active |
US8129346 | Compounds for enzyme inhibition |
14 Apr, 2025
(3 months from now)
| Active |
US8207125 | Compounds for enzyme inhibition |
14 Apr, 2025
(3 months from now)
| Active |
US8207126 | Compounds for enzyme inhibition |
14 Apr, 2025
(3 months from now)
| Active |
US8207127 | Compounds for enzyme inhibition |
14 Apr, 2025
(3 months from now)
| Active |
US8207297 | Compounds for enzyme inhibition |
14 Apr, 2025
(3 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Kyprolis's drug page